On August 28, 2018 Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing a patient-specific T-cell product designed to be delivered following a haploidentical hematopoietic stem cell transplant, or HSCT, in order to support the patient’s newly transplanted immune system before it becomes fully functional, reported that it is scheduled to attend the following investor conferences in September 2018 (Press release, Kiadis, AUG 28, 2018, View Source [SID1234529092]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs 8th Annual Biotech Symposium

September 7, 2018, Goldman Sachs Offices, River Court, 120 Fleet Street, London, UK

Oppenheimer Fall Summit focused on Specialty Pharma and Rare Disease

September 26-27, 2018, The Langham, 400 5th Avenue, New York, USA

KBC Securities 6th Biotech and Healthcare Conference

September 27, 2018, Convene Grand Central, 101 Park Avenue, New York, USA

For more information, please contact:

Kiadis Pharma:

Karl Hård, Head of IR & Communications

Tel. +31 611 096 298

[email protected]

Optimum Strategic Communications:

Mary Clark, Supriya Mathur, Hollie Vile

Tel: +44 203 714 1787

[email protected]

On August 28, 2018 Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) reported it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC (Press release, Aurinia Pharmaceuticals, AUG 28, 2018, https://ir.auriniapharma.com/news/detail/122/aurinia-announces-participation-at-the-20th-annual-global-investment-conference-in-new-york-city-september-4-6-2018 [SID1234529090]). The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Celia Economides, Vice President of Corporate and Public Affairs, will provide an overview of the Company’s business on Thursday, September 6 at 10:50am ET.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay will also be archived on the site following the event.

On August 27, 2018 Linnaeus Therapeutics, Inc. ("Linnaeus"), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, reported that it has closed a $4.4 million series A financing (Press release, Linnaeus Therapeutics, AUG 27, 2018, View Source [SID1234539508]). Kairos Ventures, of Beverly Hills, California, led the financing with significant participation from the University of Pennsylvania, Linnaeus CEO, Patrick Mooney, and Linnaeus SVP, R&D, Tina Garyantes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company intends to use the proceeds from the financing to advance its lead compound, LNS8801, through its nonclinical development with the goal of filing an Investigational New Drug Application ("IND") in the summer of 2019.

As a result of the financing, Nikos Iatropoulos, a Kairos Ventures’ partner and its chief operating officer, will be joining the company’s board of directors.

"We are very excited to have Kairos as the lead investor in our Series A round. They are the premier early-stage life science and technology investor, and they will bring tremendous value as will build Linnaeus," said Patrick Mooney, M.D., chief executive officer of Linnaeus. "With the series A proceeds we look forward to advancing LNS8801 toward an IND filing and phase 1 and 2 clinical studies that should begin in 2019."

On August 27, 2018 Biotheus Inc. reported that it will develop innovative biomedical projects valued at 800 million yuan ($125 million) in Zhuhai with revenue expected to exceed 3 billion yuan ($469 million) once production begins (Press release, Biotheus, AUG 27, 2018, View Source [SID1234533245]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The development will be a joint effort with the Zhuhai National Hi-Tech Industrial Development Zone (Tangjiawan) Administrative Committee as stipulated in a cooperation agreement signed on Aug 23.

Biotheus is a specialized researcher of brand-new biomedicine in line with advanced international standards. Established this March in the Technological Innovation Coast, it covers 4,500 sq m (1.1 acres).

The company will research and develop a new generation of monoclonal antibodies, recombinant proteins, and peptide biopharmaceuticals. The partnership deal covers six projects seeking first-class bio drugs, including four targeting improvements in tumor immunotherapy and two looking into metabolic disease treatment.

The projects are to be implemented by a professional team with extensive experience in R&D, industrialization, and management in the biomedicine sector. Chief among them are Liu Xiaolin, CEO of the company, who was previously the senior vice president at Innovent Biologics, and Lyu Qiang, chairman of the company and an expert listed in the national Thousand Talent Program.

Researchers at Prometheus Bio-technology

Staffers involved have participated in more than 40 R&D projects, and the products resulting from their efforts now reap $20 billion in annual sales, according to a manager.

Lyu said the company hopes to lead the Pearl River Delta in contract development and manufacturing organization in biomedicine and will promote the growth of related industries.

On August 27, 2018 BioCanCell Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, reported that the company is changing its name to Anchiano Therapeutics (Press release, BioCancell Therapeutics, AUG 27, 2018, View Source [SID1234532563]). Anchiano Therapeutics remains publicly traded on the Tel Aviv Stock Exchange under the ticker symbol "ANCN" (formerly "BICL").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have undergone a transformation over the last two years, opening our office in Cambridge, bringing our clinical development team aboard, and preparing our pivotal clinical development program for execution in the US and internationally. Our new name, Anchiano Therapeutics, reflects the next stage in our evolution," said Frank Haluska, M.D., Ph.D., President and Chief Executive Officer of Anchiano Therapeutics. "Anchiano is the birthplace of Leonardo da Vinci. It is our symbolic wellspring of the innovation and artistry in science that lies at the foundation of our commitment to bringing new approaches to the treatment of cancer. The first of these, our experimental gene therapy for early bladder cancer with inodiftagene vixteplasmid, will enter its initial pivotal study, the Codex Trial, later this year."